InMed Pharmaceuticals Inc. Quarterly Cost of Revenue in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
InMed Pharmaceuticals Inc. quarterly/annual Cost of Revenue history and growth rate from Q4 2021 to Q3 2024.
  • InMed Pharmaceuticals Inc. Cost of Revenue for the quarter ending September 30, 2024 was $771K, a 12.4% decline year-over-year.
  • InMed Pharmaceuticals Inc. annual Cost of Revenue for 2024 was $3.5M, a 28% increase from 2023.
  • InMed Pharmaceuticals Inc. annual Cost of Revenue for 2023 was $2.73M, a 401% increase from 2022.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $771K -$109K -12.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q3 2023 $3.38M $881K +$646K +275% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $2.73M $1.32M Apr 1, 2023 Jun 30, 2023 10-K 2024-09-30
Q1 2023 $841K +$714K +561% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $339K +$185K +121% Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-17
Q3 2022 $235K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q1 2022 $127K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $154K Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.